+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Coronavirus Disease (COVID-19) Pipeline of Small and Mid-Cap Bio/Pharma Companies

  • ID: 5134504
  • Report
  • July 2020
  • Region: Global
  • 28 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Abivax SA
  • Athersys Inc
  • Cytodyn Inc
  • FibroGen Inc
  • InflaRx
  • Mesoblast Ltd
  • MORE
Summary

The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact Small and Mid Bio/Pharma Companies.

Scope
  • This PowerPoint based report gives an important expert analysis on how the developement of vaccines and therapeutics for COVID-19 has been approached by Small and Mid Cap Bio/Pharma Companies.
  • Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
Reasons to Buy
  • An overview of how Small and Mid Cap Bio/Pharma Companies have approached the developemnt of vaccines and therapeutics for the COVID-19 pandemic.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abivax SA
  • Athersys Inc
  • Cytodyn Inc
  • FibroGen Inc
  • InflaRx
  • Mesoblast Ltd
  • MORE
1 COVID-19 Pipeline of Small and Mid-Cap Companies
1.1 COVID-19 Pipeline of Small and Mid-Cap Companies
1. 2 Analysis of COVID-19 Pipeline by Phase and Type
1.3 Analysis of COVID-19 Pipeline by Market Cap

2 Vaccine Development by Small and Mid-Cap Companies
2.1 COVID-19 Vaccine Pipeline by Phase and Molecule Subtype
2.2 Highest Development Phase COVID-19 Vaccine Pipeline

3 Therapeutic Development by Small and Mid-Cap Companies
3.1 COVID-19 Therapeutic Pipeline by Phase and Molecule Type
3.2 COVID-19 Biologic Therapeutic Pipeline by Phase and Molecule Subtype
3.3 Highest Development Phase COVID-19 Therapeutic Pipeline

4 COVID-19 Deals
4.1 COVID-19-related Partnership Agreements with Small and Mid-Cap Companies
4.2 COVID-19-related Licensing Agreements with Small and Mid-Cap Companies

5 Key Findings

6 Appendix
6.1 Glossary
6.2 Methodology
6.3 Related Reports
6.4 About the Authors
6.5 About the Publisher
6.6 Contact
Note: Product cover images may vary from those shown
3 of 3
  • Sinopharm Group Co Ltd
  • CanSino Biologics Inc
  • Novavax Inc
  • Swedish Orphan Biovitrum AB
  • Biohaven Pharmaceutical Holding Company Ltd
  • FibroGen Inc
  • Cytodyn Inc
  • Insmed Inc US
  • Mesoblast Ltd
  • Humanigen Inc
  • Vanda Pharmaceuticals Inc
  • Athersys Inc
  • Abivax SA
  • Dynavax Technologies Corp
  • Vir Biotechnology
  • Akers Biosciences Inc
  • InflaRx
Note: Product cover images may vary from those shown
Adroll
adroll